Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurocritical Care
Published in: Neurocritical Care 3/2018

01-12-2018 | Review Article

Stress Ulcer Prophylaxis in Neurocritical Care

Authors: Jeffrey F. Barletta, Alicia J. Mangram, Joseph F. Sucher, Victor Zach

Published in: Neurocritical Care | Issue 3/2018

Login to get access

Abstract

Stress ulcer prophylaxis (SUP) with acid-suppressive drug therapy is widely utilized in critically ill patients following neurologic injury for the prevention of clinically important stress-related gastrointestinal bleeding (CIB). Data supporting SUP, however, largely originates from studies conducted during an era where practices were vastly different than what is considered routine by today’s standard. This is particularly true in neurocritical care patients. In fact, the routine provision of SUP has been challenged due to an increasing prevalence of adverse drug events with acid-suppressive therapy and the perception that CIB rates are sparse. This narrative review will discuss current controversies with SUP as they apply to neurocritical care patients. Specifically, the pathophysiology, prevalence, and risk factors for CIB along with the comparative efficacy, safety, and cost-effectiveness of acid-suppressive therapy will be described.
Literature
1.
ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999;56(4):347–79.
2.
Fennerty MB. Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression. Crit Care Med. 2002;30(6 Suppl):S351–5.CrossRefPubMed
3.
Lucas CE, Sugawa C, Riddle J, Rector F, Rosenberg B, Walt AJ. Natural history and surgical dilemma of “stress” gastric bleeding. Arch Surg. 1971;102(4):266–73.CrossRefPubMed
4.
Cushing H. Peptic ulcers and the interbrain. Surg Gynecol Obstet. 1932;55:1–34.
5.
Cheung LY. Pathogenesis, prophylaxis, and treatment of stress gastritis. Am J Surg. 1988;156(6):437–40.CrossRefPubMed
6.
7.
Idjadi F, Robbins R, Stahl WM, Essiet G. Prospective study of gastric secretion in stressed patients with intracranial injury. J Trauma. 1971;11(8):681–8.CrossRefPubMed
8.
9.
Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345(20):1444–51. doi:10.​1056/​NEJMoa011258.CrossRefPubMed
10.
El Masri WE, Cochrane P, Silver JR. Gastrointestinal bleeding in patients with acute spinal injuries. Injury. 1982;14(2):162–7.CrossRefPubMed
11.
12.
Gore RM, Mintzer RA, Calenoff L. Gastrointestinal complications of spinal cord injury. Spine. 1981;6(6):538–44.CrossRefPubMed
13.
14.
15.
Walters K, Silver JR. Gastrointestinal bleeding in patients with acute spinal injuries. Int Rehabil Med. 1986;8(1):44–7.CrossRefPubMed
16.
Leramo OB, Tator CH, Hudson AR. Massive gastroduodenal hemorrhage and perforation in acute spinal cord injury. Surg Neurol. 1982;17(3):186–90.CrossRefPubMed
17.
Burgess P, Larson GM, Davidson P, Brown J, Metz CA. Effect of ranitidine on intragastric pH and stress-related upper gastrointestinal bleeding in patients with severe head injury. Dig Dis Sci. 1995;40(3):645–50.CrossRefPubMed
18.
Gudeman SK, Wheeler CB, Miller JD, Halloran LG, Becker DP. Gastric secretory and mucosal injury response to severe head trauma. Neurosurgery. 1983;12(2):175–9.CrossRefPubMed
19.
Halloran LG, Zfass AM, Gayle WE, Wheeler CB, Miller JD. Prevention of acute gastrointestinal complications after severe head injury: a controlled trial of cimetidine prophylaxis. Am J Surg. 1980;139(1):44–8.CrossRefPubMed
20.
Kamada T, Fusamoto H, Kawano S, Noguchi M, Hiramatsu K. Gastrointestinal bleeding following head injury: a clinical study of 433 cases. J Trauma. 1977;17(1):44–7.CrossRefPubMed
21.
Metz CA, Livingston DH, Smith JS, Larson GM, Wilson TH. Impact of multiple risk factors and ranitidine prophylaxis on the development of stress-related upper gastrointestinal bleeding: a prospective, multicenter, double-blind, randomized trial. Crit Care Med. 1993;21(12):1844–9.CrossRefPubMed
22.
Krag M, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, McArthur C, Cook D, Nielsen N, Pelosi P, Keus F, Guttormsen AB, Moller AD, Moller MH. Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. Intensive Care Med. 2015;41(5):833–45. doi:10.​1007/​s00134-015-3725-1.CrossRefPubMed
23.
Chan KH, Mann KS, Lai EC, Ngan J, Tuen H, Yue CP. Factors influencing the development of gastrointestinal complications after neurosurgery: results of multivariate analysis. Neurosurgery. 1989;25(3):378–82.CrossRefPubMed
24.
Misra UK, Kalita J, Pandey S, Mandal SK. Predictors of gastrointestinal bleeding in acute intracerebral haemorrhage. J Neurol Sci. 2003;208(1–2):25–9.CrossRefPubMed
25.
Liu BL, Li B, Zhang X, Fei Z, Hu SJ, Lin W, Gao DK, Zhang L. A randomized controlled study comparing omeprazole and cimetidine for the prophylaxis of stress-related upper gastrointestinal bleeding in patients with intracerebral hemorrhage. J Neurosurg. 2013;118(1):115–20. doi:10.​3171/​2012.​9.​jns12170.CrossRefPubMed
26.
Hatton J, Lu WY, Rhoney DH, Tibbs PA, Dempsey RJ, Young B. A step-wise protocol for stress ulcer prophylaxis in the neurosurgical intensive care unit. Surg Neurol. 1996;46(5):493–9.CrossRefPubMed
27.
Li ZM, Wang LX, Jiang LC, Zhu JX, Geng FY, Qiang F. Relationship between plasma cortisol levels and stress ulcer following acute and severe head injury. Med Princ Pract. 2010;19(1):17–21. doi:10.​1159/​000252829.CrossRefPubMed
28.
Cook D, Heyland D, Griffith L, Cook R, Marshall J, Pagliarello J. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Crit Care Med. 1999;27(12):2812–7.CrossRefPubMed
29.
Ellison RT, Perez-Perez G, Welsh CH, Blaser MJ, Riester KA, Cross AS, Donta ST, Peduzzi P. Risk factors for upper gastrointestinal bleeding in intensive care unit patients: role of helicobacter pylori. Crit Care Med. 1996;24(12):1974–81.CrossRefPubMed
30.
Guillamondegui OD, Gunter OL, Bonadies JA, Coates JE, Kurek SJ, DeMoya MA, Sing RF, Sori AJ. Practice management guidelines for stress ulcer prophylaxis. 2008. www.​east.​org. Accessed 24 Aug 2015.
31.
Simons RK, Hoyt DB, Winchell RJ, Holbrook T, Eastman AB. A risk analysis of stress ulceration after trauma. J Trauma. 1995;39(2):289–93 (discussion 293-284).CrossRefPubMed
32.
33.
34.
Daley RJ, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: current trends in critical care. Crit Care Med. 2004;32(10):2008–13.CrossRefPubMed
35.
Eastwood GM, Litton E, Bellomo R, Bailey MJ, Festa M, Beasley RW, Young PJ. Opinions and practice of stress ulcer prophylaxis in Australian and New Zealand intensive care units. Crit Care Resusc. 2014;16(3):170–4.PubMed
36.
37.
38.
Krag M, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, McArthur C, Cook D, Nielsen N, Pelosi P, Keus F, Guttormsen AB, Moller AD, Moller MH. Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries. Acta Anaesthesiol Scand. 2015;59(5):576–85. doi:10.​1111/​aas.​12508.CrossRefPubMed
39.
Lam NP, Le PD, Crawford SY, Patel S. National survey of stress ulcer prophylaxis. Crit Care Med. 1999;27(1):98–103.CrossRefPubMed
40.
Preslaski CR, Mueller SW, Kiser TH, Fish DN, MacLaren R. A survey of prescriber perceptions about the prevention of stress-related mucosal bleeding in the intensive care unit. J Clin Pharm Ther. 2014;39(6):658–62. doi:10.​1111/​jcpt.​12208.CrossRefPubMed
41.
Shears M, Alhazzani W, Marshall JC, Muscedere J, Hall R, English SW, Dodek PM, Lauzier F, Kanji S, Duffett M, Barletta J, Alshahrani M, Arabi Y, Deane A, Cook DJ. Stress ulcer prophylaxis in critical illness: a Canadian survey. Can J Anaesth. 2016;63(6):718–24. doi:10.​1007/​s12630-016-0612-3.CrossRefPubMed
42.
Brophy GM, Brackbill ML, Bidwell KL, Brophy DF. Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patients. Neurocrit Care. 2010;13(2):176–81. doi:10.​1007/​s12028-010-9397-3.CrossRefPubMed
43.
Chan KH, Lai EC, Tuen H, Ngan JH, Mok F, Fan YW, Fung CF, Yu WC. Prospective double-blind placebo-controlled randomized trial on the use of ranitidine in preventing postoperative gastroduodenal complications in high-risk neurosurgical patients. J Neurosurg. 1995;82(3):413–7. doi:10.​3171/​jns.​1995.​82.​3.​0413.CrossRefPubMed
44.
Lee TH, Hung FM, Yang LH. Comparison of the efficacy of esomeprazole and famotidine against stress ulcers in a neurosurgical intensive car unit. Adv Dig Med. 2014;1:50–3.CrossRef
45.
Misra UK, Kalita J, Pandey S, Mandal SK, Srivastava M. A randomized placebo controlled trial of ranitidine versus sucralfate in patients with spontaneous intracerebral hemorrhage for prevention of gastric hemorrhage. J Neurol Sci. 2005;239(1):5–10. doi:10.​1016/​j.​jns.​2005.​07.​011.CrossRefPubMed
46.
Reusser P, Gyr K, Scheidegger D, Buchmann B, Buser M, Zimmerli W. Prospective endoscopic study of stress erosions and ulcers in critically ill neurosurgical patients: current incidence and effect of acid-reducing prophylaxis. Crit Care Med. 1990;18(3):270–4.CrossRefPubMed
47.
48.
Conrad SA, Gabrielli A, Margolis B, Quartin A, Hata JS, Frank WO, Bagin RG, Rock JA, Hepburn B, Laine L. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med. 2005;33(4):760–5.CrossRefPubMed
49.
Kantorova I, Svoboda P, Scheer P, Doubek J, Rehorkova D, Bosakova H, Ochmann J. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology. 2004;51(57):757–61.PubMed
50.
Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci. 1997;42(6):1255–9.CrossRefPubMed
51.
Solouki M, Marashian S, Kouchak M. Comparison between the preventive effects of ranitidine and omeprazole on upper gastrointestinal bleeding among ICU patients. Tanaffos. 2009;8:37–42.
52.
Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, Peters S, Rutledge F, Griffith L, McLellan A, Wood G, Kirby A. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med. 1998;338(12):791–7. doi:10.​1056/​nejm199803193381​203.CrossRefPubMed
53.
Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41(3):693–705. doi:10.​1097/​CCM.​0b013e3182758734​.CrossRefPubMed
54.
Alshamsi F, Belley-Cote E, Cook D, Almenawer SA, Alqahtani Z, Perri D, Thabane L, Al-Omari A, Lewis K, Guyatt G, Alhazzani W. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care. 2016;20(1):120. doi:10.​1186/​s13054-016-1305-6.CrossRefPubMedPubMedCentral
55.
Barkun AN, Bardou M, Pham CQ, Martel M. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol. 2012;107(4):507–20. doi:10.​1038/​ajg.​2011.​474 (quiz 521).CrossRefPubMed
56.
Lin PC, Chang CH, Hsu PI, Tseng PL, Huang YB. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. Crit Care Med. 2010;38(4):1197–205. doi:10.​1097/​CCM.​0b013e3181d69ccf​.CrossRefPubMed
57.
Pongprasobchai S, Kridkratoke S, Nopmaneejumruslers C. Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: a meta-analysis. J Med Assoc Thai. 2009;92(5):632–7.PubMed
58.
59.
Barletta JF. Histamine-2-receptor antagonist administration and gastrointestinal bleeding when used for stress ulcer prophylaxis in patients with severe sepsis or septic shock. Ann Pharmacother. 2014;48(10):1276–81. doi:10.​1177/​1060028014540513​.CrossRefPubMed
60.
Faisy C, Guerot E, Diehl JL, Iftimovici E, Fagon JY. Clinically significant gastrointestinal bleeding in critically ill patients with and without stress-ulcer prophylaxis. Intensive Care Med. 2003;29(8):1306–13. doi:10.​1007/​s00134-003-1863-3.CrossRefPubMed
61.
Krag M, Perner A, Wetterslev J, Wise MP, Hylander Moller M. Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med. 2014;40(1):11–22. doi:10.​1007/​s00134-013-3125-3.CrossRefPubMed
62.
63.
Selvanderan SP, Summers MJ, Finnis ME, Plummer MP, Ali Abdelhamid Y, Anderson MB, Chapman MJ, Rayner CK, Deane AM. Pantoprazole or placebo for stress ulcer prophylaxis (POP-UP): randomized double-blind exploratory study. Crit Care Med. 2016;44(10):1842–50. doi:10.​1097/​ccm.​0000000000001819​.CrossRefPubMed
64.
Alhazzani W, Guyatt G, Alshahrani M, Deane AM, Marshall JC, Hall R, Muscedere J, English SW, Lauzier F, Thabane L, Arabi YM, Karachi T, Rochwerg B, Finfer S, Daneman N, Alshamsi F, Zytaruk N, Heel-Ansdell D, Cook D. Withholding pantoprazole for stress ulcer prophylaxis in critically Ill patients: a pilot randomized clinical trial and meta-analysis. Crit Care Med. 2017;45(7):1121–9. doi:10.​1097/​ccm.​0000000000002461​.CrossRefPubMed
65.
Krag M, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, Pelosi P, Keus F, Guttormsen AB, Schefold JC, Moller MH. Stress ulcer prophylaxis with a proton pump inhibitor versus placebo in critically ill patients (SUP-ICU trial): study protocol for a randomised controlled trial. Trials. 2016;17(1):205. doi:10.​1186/​s13063-016-1331-3.CrossRefPubMedPubMedCentral
66.
67.
68.
Young P. A multi-centre, cluster randomised, crossover, registry trial comparing the safety and efficacy of proton pump inhibitors with histamine-2 receptor blockers for ulcer prophylaxis in intensive care patients requiring invasive mechanical intervention. In: Australian and New Zealand Clinical Trials Registry [Internet]: Sydney (NSW): National Health and Medical Research Council (Australia). 2005—[cited 2017 Aug 1]. https://​www.​anzctr.​org.​au/​Trial/​Registration/​TrialReview.​aspx?​id=​370438&​isReview=​true Identifier ACTRN12616000481471.
69.
Hurt RT, Frazier TH, McClave SA, Crittenden NE, Kulisek C, Saad M, Franklin GA. Stress prophylaxis in intensive care unit patients and the role of enteral nutrition. JPEN J Parenter Enteral Nutr. 2012;36(6):721–31. doi:10.​1177/​0148607112436978​.CrossRefPubMed
70.
MacLaren R, Jarvis CL, Fish DN. Use of enteral nutrition for stress ulcer prophylaxis. Ann Pharmacother. 2001;35(12):1614–23.CrossRefPubMed
71.
72.
73.
Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30(5):1118–22.CrossRefPubMed
74.
Azevedo J, Soares M, Silva G. Prevention of stress ulcer bleeding in high risk patients. Comparison of three drugs. Gastrenterologia Endosc. Dig. 2000;19:239–44.
75.
Bashar FR, Manuchehrian N, Mahmoudabadi M, Hajiesmaeili MR, Torabian S. Effects of ranitidine and pantoprazole on ventilator-associated pneumonia: a randomized double-blind clinical trial. Tanaffos. 2013;12(2):16–21.PubMedPubMedCentral
76.
Solouki M, Mar’ashian SM, Koochak M, Nasiri A, Mokhtari M, Amirpour A. Ventilator-associated pneumonia among ICU patients receiving mechanical ventilation and prophylaxis of gastrointestinal bleeding. Iranian J. Clin. Infect. Dis. 2009;4(3):177–80.
77.
Somberg L, Morris J Jr, Fantus R, Graepel J, Field BG, Lynn R, Karlstadt R. Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease. J Trauma. 2008;64(5):1202–10. doi:10.​1097/​TA.​0b013e31815e40b5​.CrossRefPubMed
78.
Alquraini M, Alshamsi F, Moller MH, Belley-Cote E, Almenawer S, Jaeschke R, MacLaren R, Alhazzani W. Sucralfate versus histamine 2 receptor antagonists for stress ulcer prophylaxis in adult critically ill patients: a meta-analysis and trial sequential analysis of randomized trials. J Crit Care. 2017;40:21–30. doi:10.​1016/​j.​jcrc.​2017.​03.​005.CrossRefPubMed
79.
Cook DJ, Laine LA, Guyatt GH, Raffin TA. Nosocomial pneumonia and the role of gastric pH. A meta-analysis. Chest. 1991;100(1):7–13.CrossRefPubMed
80.
Cook DJ, Reeve BK, Guyatt GH, Heyland DK, Griffith LE, Buckingham L, Tryba M. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA. 1996;275(4):308–14.CrossRefPubMed
81.
82.
Huang J, Cao Y, Liao C, Wu L, Gao F. Effect of histamine-2-receptor antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients: a meta-analysis of 10 randomized controlled trials. Crit Care. 2010;14(5):R194. doi:10.​1186/​cc9312.CrossRefPubMedPubMedCentral
83.
Messori A, Trippoli S, Vaiani M, Gorini M, Corrado A. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ. 2000;321(7269):1103–6.CrossRefPubMedPubMedCentral
84.
Tryba M. Prophylaxis of stress ulcer bleeding. A meta-analysis. J Clin Gastroenterol. 1991;13(Suppl 2):S44–55.PubMed
85.
Tryba M. Sucralfate versus antacids or H2-antagonists for stress ulcer prophylaxis: a meta-analysis on efficacy and pneumonia rate. Crit Care Med. 1991;19(7):942–9.CrossRefPubMed
86.
Bateman BT, Bykov K, Choudhry NK, Schneeweiss S, Gagne JJ, Polinski JM, Franklin JM, Doherty M, Fischer MA, Rassen JA. Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. BMJ. 2013;347:f5416. doi:10.​1136/​bmj.​f5416.CrossRefPubMedPubMedCentral
87.
88.
89.
90.
91.
92.
Karanika S, Paudel S, Zervou FN, Grigoras C, Zacharioudakis IM, Mylonakis E. Prevalence and clinical outcomes of clostridium difficile infection in the intensive care unit: a systematic review and meta-analysis. Open Forum Infect Dis. 2016;3(1):ofv186. doi:10.​1093/​ofid/​ofv186.CrossRefPubMed
93.
94.
95.
96.
Beaulieu M, Williamson D, Pichette G, Lachaine J. Risk of clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit. Infect Control Hosp Epidemiol. 2007;28(11):1305–7. doi:10.​1086/​521664.CrossRefPubMed
97.
Buendgens L, Bruensing J, Matthes M, Duckers H, Luedde T, Trautwein C, Tacke F, Koch A. Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea. J Crit Care. 2014;29(4):696-e611. doi:10.​1016/​j.​jcrc.​2014.​03.​002.CrossRef
98.
Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003;54(3):243–5.CrossRefPubMed
99.
100.
Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171(1):33–8.CrossRefPubMedPubMedCentral
101.
102.
103.
Jayatilaka S, Shakov R, Eddi R, Bakaj G, Baddoura WJ, DeBari VA. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci. 2007;37(3):241–7.PubMed
104.
Lewis PO, Litchfield JM, Tharp JL, Garcia RM, Pourmorteza M, Reddy CM. Risk and severity of hospital-acquired clostridium difficile infection in patients taking proton pump inhibitors. Pharmacotherapy. 2016;36(9):986–93. doi:10.​1002/​phar.​1801.CrossRefPubMed
105.
Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T, Croyle K, Krystofiak S, Patel-Brown S, Pasculle AW, Paterson DL, Saul M, Harrison LH. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26(3):273–80. doi:10.​1086/​502539.CrossRefPubMed
106.
Nath SK, Salama S, Persaud D, Thornley JH, Smith I, Foster G, Rotstein C. Drug risk factors associated with a sustained outbreak of Clostridium difficile diarrhea in a teaching hospital. Can J Infect Dis. 1994;5(6):270–5.CrossRefPubMedPubMedCentral
107.
Pakyz AL, Jawahar R, Wang Q, Harpe SE. Medication risk factors associated with healthcare-associated Clostridium difficile infection: a multilevel model case-control study among 64 US academic medical centres. J Antimicrob Chemother. 2014;69(4):1127–31. doi:10.​1093/​jac/​dkt489.CrossRefPubMed
108.
Peled N, Pitlik S, Samra Z, Kazakov A, Bloch Y, Bishara J. Predicting Clostridium difficile toxin in hospitalized patients with antibiotic-associated diarrhea. Infect Control Hosp Epidemiol. 2007;28(4):377–81. doi:10.​1086/​513723.CrossRefPubMed
109.
Shaughnessy MK, Micielli RL, DePestel DD, Arndt J, Strachan CL, Welch KB, Chenoweth CE. Evaluation of hospital room assignment and acquisition of Clostridium difficile infection. Infect Control Hosp Epidemiol. 2011;32(3):201–6. doi:10.​1086/​658669.CrossRefPubMed
110.
111.
Stevens V, Dumyati G, Brown J, Wijngaarden E. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure. Pharmacoepidemiol Drug Saf. 2011;20(10):1035–42. doi:10.​1002/​pds.​2198.CrossRefPubMed
112.
113.
114.
Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–9. doi:10.​1038/​ajg.​2012.​108.CrossRefPubMed
115.
Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55. doi:10.​1086/​651706.CrossRefPubMed
116.
117.
Cawley MJ, Wittbrodt ET, Boyce EG, Skaar DJ. Potential risk factors associated with thrombocytopenia in a surgical intensive care unit. Pharmacotherapy. 1999;19(1):108–13.CrossRefPubMed
118.
119.
Shalansky SJ, Verma AK, Levine M, Spinelli JJ, Dodek PM. Risk markers for thrombocytopenia in critically ill patients: a prospective analysis. Pharmacotherapy. 2002;22(7):803–13.CrossRefPubMed
120.
Williamson DR, Albert M, Heels-Ansdell D, Arnold DM, Lauzier F, Zarychanski R, Crowther M, Warkentin TE, Dodek P, Cade J, Lesur O, Lim W, Fowler R, Lamontagne F, Langevin S, Freitag A, Muscedere J, Friedrich JO, Geerts W, Burry L, Alhashemi J, Cook D. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest. 2013;144(4):1207–15. doi:10.​1378/​chest.​13-0121.CrossRefPubMed
121.
122.
123.
Henann NE, Carpenter DU, Janda SM. Famotidine-associated mental confusion in elderly patients. Drug Intell Clin Pharm. 1988;22(12):976–8.CrossRefPubMed
124.
Odeh M, Oliven A. Central nervous system reactions associated with famotidine: report of five cases. J Clin Gastroenterol. 1998;27(3):253–4.CrossRefPubMed
125.
126.
Hammond DA, Kathe N, Shah A, Martin BC. Cost-effectiveness of Histamine2 receptor antagonists versus proton pump inhibitors for stress ulcer prophylaxis in critically Ill patients. Pharmacotherapy. 2017;37(1):43–53. doi:10.​1002/​phar.​1859.CrossRefPubMed
127.
128.
Udeh BL, Udeh C, Hata JS. Cost-effectiveness of stress ulcer prophylaxis: role of proton pump inhibitors. Am J Pharm Benefits. 2010;2(5):304–12.
Metadata
Title
Stress Ulcer Prophylaxis in Neurocritical Care
Authors
Jeffrey F. Barletta
Alicia J. Mangram
Joseph F. Sucher
Victor Zach
Publication date
01-12-2018
Publisher
Springer US
Published in
Neurocritical Care / Issue 3/2018
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-017-0447-y

Other articles of this Issue 3/2018

Neurocritical Care 3/2018 Go to the issue

Original Article

Successful Wean Despite Emergence of Ictal–Interictal EEG Patterns During the Weaning of Prolonged Burst-Suppression Therapy for Super-Refractory Status Epilepticus

Original Article

Effects of Diabetes Mellitus and Admission Glucose in Patients Receiving Mechanical Thrombectomy: A Systematic Review and Meta-analysis

Practical Pearl

A Callosal Catastrophe: Toxic Leukoencephalopathy Associated with Thermogenic Weight Loss Supplement Use

Practical Pearl

Medulla Oblongata Hemorrhage and Reverse Takotsubo Cardiomyopathy

Original Article

Impact of Acute Cardiac Complications After Subarachnoid Hemorrhage on Long-Term Mortality and Cardiovascular Events

Letter to the Editor

Neurological Disease Triggering Takotsubo Syndrome